Tag Archives: GlaxoSmithKline

GSK anti-BCMA security issues? FDA panel turns a blind eye

Last week, FDA staff raised concerns about eye-related side effects that may come with GlaxoSmithKline’s BCMA cancer treatment. Despite questions about whether those problems, which include loss of vision, so severe patients stopped reading or driving, could be effectively identified and managed, the drug came out of an advisory committee …

Read More »

Tata Motors dismisses Rs 1k cr NCD offer in ‘tight’ mkt

[ad_1] MUMBAI: Tata Motors, the flagship of the largest conglomerate in India Tata Group, has withdrawn plans to launch a Rs 1 billion non-convertible bond (ENT) offering, citing “higher cost expectations from participants due to tight money market conditions.” The decision comes two days after the company approved the issuance …

Read More »